Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 8 Head & Neck 4 Gynecologic 3 Gastrointestinal 3 CNS 3 Thoracic 2 Other hematologic neoplasm 2 Tumor-Agnostic 1 Sarcoma 1 Myeloid 1 Genitourinary 1 Breast 1

Conditions

Muscle Invasive Bladder Cancer 1

Interventions

pembrolizumab 93 Nivolumab 61 Docetaxel 55 Cyclophosphamide 49 enzalutamide 44 Magnetic Resonance Spectroscopy 33 Ipilimumab 33 Gemcitabine 32 Abiraterone Acetate 30 Prednisone 29 fludarabine 28 Everolimus 27 Paclitaxel 25 Cisplatin 24 Radiotherapy 23 Carboplatin 23 Sunitinib 22 cabozantinib 21 atezolizumab 20 Radiosurgery 20 Specimen Handling 19 Sorafenib 18 Bevacizumab 18 pazopanib 17 bicalutamide 17 abiraterone 17 Biopsy 15 temsirolimus 14 darolutamide 14 apalutamide 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × adavosertib × Genitourinary × Clear all

NCT02546661 2025-12-29

BISCAY

AstraZeneca

Phase 1 Active not recruiting

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡